Acuitas: (noun) insight, perception, sharpness.

FEATURED

Vancouver-based Acuitas Therapeutics Makes History with First COVID-19 Vaccine Approved for Use in Canada

Click to see a news release regarding our partner, BioNTech (with Pfizer), on the Health Canada emergency use authorization of their COVID-19 vaccine. Our proprietary lipid nanoparticles are an important aspect of BioNTech’s mRNA vaccine. More >

A Look into Acuitas Therapeutics’ Lipid Nanoparticle Delivery System Technology

Click to see an article regarding our proprietary lipid nanoparticle delivery system technology used in the BioNTech/Pfizer COVID-19 vaccine in this BioPharm International article. More >

Acuitas Announces Publication of Research in Nature

Click to see a news release regarding publication of Acuitas research results in the prestigious journal Nature, from the company’s work as part of a collaboration with Verve Therapeutics, Inc. More >

OTHER NEWS

Video Alert
News Alert
  • Jul. 27, 2021 – Click to see a news release regarding Steve Arns joining Acuitas Therapeutics as the Director of Chemistry. More >
  • May 19, 2021 – Click to see a news release regarding publication of Acuitas research results in the prestigious journal Nature Biotechnology, from the company’s work as part of a collaboration with Dr. Schwank. More >
  • May 19, 2021 – Click to see a news release regarding publication of Acuitas research results in the prestigious journal Nature, from the company’s work as part of a collaboration with Verve Therapeutics, Inc. More >
  • Apr. 5, 2021 – Click to see a news release regarding Abi Coman-Walker joining Acuitas Therapeutics as the Finance & Operations Senior Director. More >
  • Feb. 5, 2021 – Click to see a news release regarding Dr. Madden’s participation in a panel led by the prestigious Gairdner Foundation. More >
  • Dec. 9, 2020 – Click to see a news release regarding our partner, BioNTech (with Pfizer), on the Health Canada emergency use authorization of their COVID-19 vaccine. Our proprietary lipid nanoparticles are an important aspect of BioNTech’s mRNA vaccine. More >
  • Nov. 9, 2020 – Click to see a news release regarding our partner, BioNTech, and their Phase 3 data for a COVID-19 vaccine. Our proprietary lipid nanoparticles are an important aspect of BioNTech’s mRNA vaccine. More >
  • Nov. 3, 2020 – Click to see a news release regarding our partner, CureVac, and their clinical trial data for a COVID-19 vaccine. Our proprietary lipid nanoparticles are an important aspect of CureVac’s mRNA vaccine. More >
  • Jul. 1, 2020 – Click to see a news release regarding our partner, BioNTech, and their clinical trial data for a COVID-19 vaccine. Our proprietary lipid nanoparticles are an important aspect of BioNTech’s mRNA vaccine. More >
  • Mar. 30, 2020 – Our President and CEO, Dr. Thomas Madden, has been inducted into the very prestigious American Institute for Medical and Biological Engineering (AIMBE) College of Fellows. More >
Publication Alert
  • June 21, 2021 – Collaboration with Dr. Angov in the development of messenger RNA expressing PfCSP that induces functional, protective immune responses against malaria in mice (Walter Reed Army Institute of Research 2021). More >
  • May 19, 2021 – Collaboration with Dr. Schwank in the development of in vivo adenine base editing of PCSK9 in macaques that reduce LDL cholesterol levels (Nat Biotech 2021). More >
  • May 19, 2021 – Collaboration with Verve Therapeutics, Inc. in the development of non-viral lipid nanoparticle (LNP) delivery technologies for single-course in vivo, liver-targeted gene editing treatments for cardiovascular disease, the leading cause of death worldwide (Nature 2021). More >
  • Jan. 27, 2021 – Collaboration with Dr. Weissman in the development of murine liver repair via transient activation of regenerative pathways in hepatocytes using lipid nanoparticle-complexed nucleoside-modified mRNA (Nature Communications 2021). More >
  • Jan. 26, 2021 – Collaboration with Dr. Schwank in the development of in vivo cytidine base editing of hepatocytes without detectable off-target mutations in RNA and DNA (Nature Biomedical Engineering 2021). More >
  • Dec. 24, 2020 – Collaboration with Dr. Weissman in the development of D614G spike mutation that increases SARS CoV-2 susceptibility to neutralization (Cell Host Microbe 2020). More >
  • Dec. 1, 2020 – Collaboration with Dr. Locci in the development of potent antigen-specific germinal center responses associated with neutralizing antibody generation in SARS-CoV-2 mRNA vaccines (Immunity 2020). More >
  • Aug. 25, 2020 – Collaboration with Dr. Pardi in the development of nucleoside-modified mRNA vaccines against SARS-CoV-2 (Immunity 2020). More >
  • Jul. 9, 2020 – Collaboration with Dr. Shattock in the development of a SARS-CoV2 vaccine using self-amplifying RNA encapsulated in LNP (Nat Commun 2020). More >
  • Jun. 30, 2020 – Collaboration with Dr. Nachbagauer in the development of a universal influenza virus vaccine (Mol Ther 2020). More >
  • Jun. 30, 2020 – Collaboration with Dr. Kurtis in the development of a vaccine based on PfGARP that partially protects subjects against malaria challenge (Nature 2020). More >
  • Jan. 30, 2020 – Collaboration with Dr. Muzykantov in the development of mRNA-LNP targeting cerebral Vasculature (Proc Natl Acad Sci U S A. 2020). More >
  • Jan. 30, 2020 – Collaboration with Dr. Hensley in the development of mRNA-LNP vaccine for infants (Sci Transl Med. 2020). More >
  • Sep. 20, 2019 – Collaboration with Dr. Sanders in the delivery of self-amplifying mRNA with LNPs (Mol Ther Nucleic Acids 2019). More >
  • Apr. 12, 2019 – Collaboration with Dr. Weissman in the development of mRNA-LNP for HIV vaccine (Mol Ther Nucleic Acids 2019). More >
  • Apr. 12, 2019 – Collaboration with Dr. Lee and colleagues in the development of ZFN mRNA-LNP for in vivo genome editing (Mol Ther 2019). More >
  • Nov. 22, 2018 – Collaboration with Dr. Muzykantov in the development of targeting mRNA-LNP (J Control Release 2018 Dec 10;291:106-115). More >
  • Aug. 22, 2018 – Collaboration with Dr. Weissman in the development of broadly protective/universal influenza virus vaccine using mRNA-LNP (Nat Commun. 2018 Aug. 22; 9(1): 3361). More >